50 mg is orally administered once weekly in patients  with moderate renal impairment. The comparative drug (Daily DPP-4 inhibitor) group: An inhibitor is orally administered at the dosage and administration in the package inserts for each drug.  ,
Duration of treatment:  12 weeks  ,Duration of evaluation:  16 weeks (Screening period: 4 weeks; treatment period: 12 weeks)  
"Eligibility of study subjects shall be determined in accordance with the following criteria.  1. Patients diagnosed as type 2 diabetes.   2. Patients with a stable diet and exercise therapy only for at least 12 weeks prior to the start of the screening period.   3. Patients who require a DPP-4 inhibitor treatment.   4. Patients with HbA1c ≥6.5 % and <10.0 % at the start of the screening period.   5. Patients who completed DTR-QOL questionnaire at the start of the screening period.   6. Patients who have receive less than 2 types of medication for treatment of comorbidities (such as hypertension or dyslipidemia) at the start of the screening period (any number of daily doses).   7. Patients who, in the opinion of the principal investigator or the investigator, are capable of understanding the content of the clinical study and complying with the study protocol requirements.   8. Patients who can provide the written informed consent prior to the initiation of any study procedures.   9. Patients aged ≥20 years at the time of informed consent.   10. Outpatient.    "
Exclusion criteria:  Study subjects meeting any of the criteria below shall not be included in this study.  1. Patients who are receiving any oral anti-diabetic medication for the treatment of type 2 diabetes at the start of the screening period.   2. Patients diagnosed as type 1 diabetes.    
